Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.49 |
| ▸ | RAF1 | P04049 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 7/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13315136 | 0.75 | ALDH1A1 (0.61) | ALDH1A1NPSR1TSHRCNR2MEN1 | |
| SCHEMBL13487547 | 0.74 | MAPK14 (0.56) | MAPK14RAF1YEATS4 | |
| SCHEMBL13487583 | 0.72 | MAPK14 (0.49) | ALDH1A1MAPK14RAF1CNR2MEN1 | |
| SCHEMBL13487574 | 0.69 | MAPK14 (0.56) | MAPK14 | |
| SCHEMBL3242374 | 0.66 | MAPK14 (1.00) | MAPK14RAF1 | |
| SCHEMBL3241912 | 0.65 | MAPK14 (0.80) | MAPK14RAF1MEN1KMT2AHTT | |
| SCHEMBL3241549 | 0.64 | MAPK14 (0.76) | ALDH1A1NPSR1MAPK14RAF1MEN1 | |
| SCHEMBL15613181 | 0.63 | KDM4E (0.67) | ALDH1A1NPSR1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL13487559 | 0.62 | MAPK14 (0.53) | ALDH1A1MAPK14CNR2SMN1; SMN2MAPT | |
| SCHEMBL3229662 | 0.61 | MAPK14 (1.00) | ALDH1A1MAPK14RAF1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | ALDH1A1 3577/4885NPSR1 4769/4885TSHR 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.